IP Library › Granted Patent US 12,357,608
Granted Patent B2
US 12,357,608 · App. 18/211,792 · Granted Jul 15, 2025

Methods and compositions utilizing RRx-001 combination therapy for radioprotection

Inventors: Bryan T. Oronsky (La Jolla, CA); Arnold Oronsky (La Jolla, CA); Tony R. Reid (La Jolla, CA)
Assignee: EPICENTRX, INC.
A61K31/397A61K9/0014A61K9/0019A61K9/0053A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,357,608
App. No.
18/211,792
Granted
Jul 15, 2025
Kind
B2
Abstract

Provided herein are therapeutic methods, kits, and pharmaceutical compositions for protecting a subject from radiation using a therapeutic agent selected from the group consisting of RRx-OO1 and a pharmaceutically acceptable salt thereof. One exemplary therapeutic method involves administering RRx-OO1 to the subject prior to the subject being exposed to the radiation, in order to protect the subject against radiation, such as ionizing radiation containing α-rays, β-rays, γ-rays, neutron radiation, or a combination thereof.

Claims (59)

1. A method for treating a subject in need of protection against radiation or for reducing radiation-exposure damage to a subject, comprising administering to the subject in need thereof a radiotherapeutic combination comprising:

(i) an effective amount of a first therapeutic agent selected from the group consisting of RRx-001 and a pharmaceutically acceptable salt thereof; and

(ii) an effective amount of a second therapeutic agent that reduces the effect of radiation on a subject,

to thereby protect the subject against radiation or to reduce the radiation-exposure damage to the subject, wherein administration of the radiotherapeutic combination reduces or inhibits radiation-exposure damage to one or more cells, systems, organs, or normal tissues in the subject.

2. The method of claim 1 , wherein the administering achieves protection against radiation for the subject or reduces the radiation-exposure damage to the subject for a duration of at least 6 hours, at least 12 hours, at least 36 hours, at least 48 hours, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 1 week, at least 2 weeks, at least 3 weeks, at least 4 weeks, or longer.

3. The method of claim 1 , wherein at least one dose of the effective amount of the first therapeutic agent and at least one dose of the effective amount of the second therapeutic agent are administered to the subject between 24 and 48 hours prior to exposure to the radiation.

4. The method of claim 1 , wherein the effective amount of the first therapeutic agent is in an amount ranging from about 0.01 mg to about 500 mg of RRx-001, about 0.1 mg to about 200 mg of RRx-001, or about 0.5 mg to about 150 mg of RRx-001.

5. The method of claim 1 , wherein at least one of the first therapeutic agent and the second therapeutic agent is administered by a route selected from the group consisting of parenteral administration, oral administration, and topical administration.

6. The method of claim 1 , wherein at least one of the first therapeutic agent and the second therapeutic agent is administered intravenously, subcutaneously, or intraperitoneally to the subject as a single bolus injection, as multiple injections, or is infused over a time period.

7. The method of claim 6 , wherein the time period is at least thirty minutes.

8. The method of claim 6 , wherein the at least one of the first therapeutic agent and the second therapeutic agent is administered subcutaneously by a subcutaneous injection to the subject, and wherein the time period is at least 5 minutes.

9. The method of claim 6 , wherein the at least one of the first therapeutic agent and the second therapeutic agent is administered subcutaneously to the subject via a pump device implanted in the subject that contains the at least one of the first therapeutic agent and the second therapeutic agent, and wherein the pump device is comprises an osmotic pump.

10. The method of claim 1 , wherein the effective amount of the first therapeutic agent and the effective amount of the second therapeutic agent are administered to the subject once per week.

11. The method of claim 1 , wherein the effective amount of the first therapeutic agent and the effective amount of the second therapeutic agent are administered to the subject at a frequency of twice per week for a time period of at least two weeks.

12. The method of claim 1 , wherein the second therapeutic agent is selected from the group consisting of amifostine, a cytokine, glutathione, N-acetyl-cysteine, iron, an iron salt, ferric oxide, a cobalt salt, a metal chelator agent, a fullerene, an agent that promotes DNA repair, a viral gene therapy that delivers Poly ADP ribose polymerase (PARP), an agent that inhibits p53 activity, an anti-TNF alpha agent, cobalt chloride, an agent that chelates iron, deferoxamine, an agent that chelates copper, an agent that chelates zinc, a polyamide, resveratrol, sodium orthovanadate, pifithrin-alpha, infliximab, etanercept, thalidomide, and pentoxifylline.

13. The method of claim 12 , wherein

the second therapeutic agent comprises amifostine, and

the amifostine is administered to the subject according to a pulse-dose regimen at a dosage ranging from about 100 mg/m 2 to about 500 mg/m 2 on any day on which the amifostine is administered to the subject.

14. The method of claim 12 , wherein

the second therapeutic agent comprises a cytokine, and

the cytokine is selected from the group consisting of interleukin 1, interleukin 2, interferon gamma, granulocyte/macrophage colony-stimulating factor, granulocyte-colony-stimulating factor, and tumor necrosis factor alpha.

15. The method of claim 1 , further comprising, prior to administering to the subject in need thereof the effective amount of the first therapeutic agent and the effective amount of the second therapeutic agent, administering to the subject at least one of a pain-relieving agent and a local analgesic agent, wherein the local analgesic agent is administered to tissue in proximity to the site of administration of the first therapeutic agent.

16. The method of claim 15 , wherein

the pain-relieving agent is selected from the group consisting of aspirin, a corticosteroid, and a non-steroidal anti-inflammatory agent (NSAID); and

the local analgesic agent is selected from the group consisting of a caine analgesic, lidocaine, lidocaine hydrochloride, VanPen cream, an NSAID, and acetaminophen.

17. The method of claim 1 , wherein

at least one of the first therapeutic agent and the second therapeutic agent are administered in proximity to tissue desired to be protected from the radiation, and

the tissue is selected from the group consisting of bone marrow, skin, pulmonary tissue, thyroid tissue, gonadal tissue, tissue of the gastrointestinal tract, skeletal tissue, and fetal tissue.

18. The method of claim 1 , wherein the subject is at risk of exposure to radiation from a nuclear emergency, or the subject is receiving radiation therapy for the treatment of a cancer.

19. The method of claim 18 , wherein the subject is receiving radiation therapy for the treatment of a cancer, and wherein the method further comprises administering an agent selected from the group consisting of an EGFR inhibitor and an inorganic nitrite salt to the subject.

20. The method of claim 19 , wherein the EGFR inhibitor is erlotinib, or a pharmaceutically acceptable salt thereof, and is administered to the subject according to a pulse-dosing schedule.

21. The method of claim 19 , wherein the inorganic nitrite salt is an alkali metal nitrite.

22. A method of protecting biological material from the damaging effects of radiation, comprising exposing the biological material to:

(i) an effective amount of a first therapeutic agent selected from the group consisting of RRx-001 and a pharmaceutically acceptable salt thereof; and

(ii) an effective amount of a second therapeutic agent that reduces the effect of radiation on a subject,

to thereby protect the biological material from the damaging effects of radiation.

23. The method of claim 22 , wherein the biological material is protected from the damaging effects of radiation for a duration of at least 6 hours, at least 12 hours, at least 36 hours, at least 48 hours, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 1 week, at least 2 weeks, at least 3 weeks, at least 4 weeks, or longer.

24. The method of claim 22 , wherein the biological material is exposed to at least one dose of the effective amount of the first therapeutic agent and at least one dose of the effective amount of the second therapeutic agent within 24 hours prior to exposure to the radiation.

25. The method of claim 22 , wherein the biological material is exposed to at least one of the effective amount of the first therapeutic agent and the effective amount of the second therapeutic agent once per week.

26. The method of claim 22 , wherein the biological material is exposed to at least one of the effective amount of the first therapeutic agent and the effective amount of the second therapeutic agent at a frequency of once per week for a time period of at least two weeks.

27. The method of claim 22 , wherein the second therapeutic agent is selected from the group consisting of amifostine, a cytokine, glutathione, N-acetyl-cysteine, iron, an iron salt, ferric oxide, a cobalt salt, a metal chelator agent, a fullerene, an agent that promotes DNA repair, a viral gene therapy that delivers Poly ADP ribose polymerase (PARP), an agent that inhibits p53 activity, an anti-TNF alpha agent, cobalt chloride, an agent that chelates iron, deferoxamine, an agent that chelates copper, an agent that chelates zinc, a polyamide, resveratrol, sodium orthovanadate, pifithrin-alpha, infliximab, etanercept, thalidomide, and pentoxifylline.

28. The method of claim 27 , wherein

the second therapeutic comprises amifostine, and

the amifostine is administered according to a pulse-dose regimen.

29. The method of claim 27 , wherein:

the second therapeutic agent comprises a cytokine, and

the cytokine is selected from the group consisting of interleukin 1, interleukin 2, interferon gamma, granulocyte/macrophage colony-stimulating factor, granulocyte-colony-stimulating factor, and tumor necrosis factor alpha.

30. The method of claim 22 , further comprising, exposing the biological material to an inorganic nitrite salt, wherein the inorganic nitrite salt is an alkali metal nitrite.

31. The method of claim 22 , wherein the biological material is selected from the group consisting of an isolated blood cell, an isolated tissue, and an isolated organ.

32. The method of claim 1 , wherein the radiation comprises α-rays, β-rays, γ-ray, x-rays, or neutron radiation.

33. The method of claim 1 , wherein the radiation is ionizing radiation from sunlight, from radioactive nuclei, or from an explosive device.

34. The method of claim 22 , wherein the subject is at risk of exposure to radiation from a nuclear emergency, or the subject is receiving radiation therapy for the treatment of a cancer.

35. The method of claim 22 , wherein the radiation comprises α-rays, β-rays, γ-rays, x-rays, or neutron radiation.

36. The method of claim 22 , wherein the radiation is ionizing radiation from sunlight, from radioactive nuclei, or from an explosive device.

37. The method of claim 1 , wherein the effective amount of the first therapeutic agent is administered to the subject at least 6 hours prior to exposure to the radiation or after the exposure to the radiation has ceased.

38. The method of claim 22 , wherein the effective amount of the first therapeutic agent is administered to the subject at least 6 hours prior to exposure to the radiation or after the exposure to the radiation has ceased.

39. The method of claim 1 , wherein the effective amount of the first therapeutic agent is at least 10 mg/kg.

40. The method of claim 22 , wherein the effective amount of the first therapeutic agent is at least 10 mg/kg.

41. The method of claim 1 , wherein administration of the radiotherapeutic combination reduces or inhibits radiation-exposure damage to one or more of bone marrow, lymphatic system, immune system, mucosal tissue, mucosal immune system, gastrointestinal system, cardiovascular system, nervous system, reproductive organs, prostate, ovaries, lung, kidney, skin, and brain.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 21, 2023
From: ORONSKY, BRYAN T.; ORONSKY, ARNOLD; REID, TONY R.
To: EPICENTRX, INC.
Reel/Frame 064333/0886 →
Continuity (5)
Continuation 17980505 · Nov 3, 2022
Continuation 16960444
Provisional Application 62737096 · Sep 26, 2018
Provisional Application 62614595 · Jan 8, 2018
Related Publication 20240148692A1 · May 9, 2024
References Cited (390)
US 2978453A · Frankel · 1961 [cited by applicant]
US 3845770A · Theeuwes et al. · 1974 [cited by applicant]
US 3916899A · Theeuwes et al. · 1975 [cited by applicant]
US 4584130A · Bucci et al. · 1986 [cited by applicant]
US 4765539A · Noakes et al. · 1988 [cited by applicant]
US 5112598A · Biesalski · 1992 [cited by applicant]
US 5336784A · Hiskey et al. · 1994 [cited by applicant]
US 5521203A · Adams et al. · 1996 [cited by applicant]
US 5556611A · Biesalski · 1996 [cited by applicant]
US 5579458A · Yokosuka et al. · 1996 [cited by applicant]
US 5580988A · Dave · 1996 [cited by applicant]
US 5607830A · Biesel et al. · 1997 [cited by applicant]
US 5679777A · Anderson et al. · 1997 [cited by applicant]
US 5693794A · Nielsen · 1997 [cited by applicant]
US 5698155A · Grosswald et al. · 1997 [cited by applicant]
US 5950619A · van der Linden et al. · 1999 [cited by applicant]
US 5954047A · Armer et al. · 1999 [cited by applicant]
US 5970974A · Van Der Linden et al. · 1999 [cited by applicant]
US 6015815A · Mollison · 2000 [cited by applicant]
US 6056966A · Selim et al. · 2000 [cited by applicant]
US 6133320A · Yallampalli et al. · 2000 [cited by applicant]
US 6245799B1 · Asselin et al. · 2001 [cited by applicant]
US 6391911B1 · Bases · 2002 [cited by applicant]
US 6407236B1 · Baraldi et al. · 2002 [cited by applicant]
US 6932962B1 · Bäckström et al. · 2005 [cited by applicant]
US 7163958B2 · Earl et al. · 2007 [cited by applicant]
US 7507842B2 · Bednarski et al. · 2009 [cited by applicant]
US 7745643B2 · Cannizzo et al. · 2010 [cited by applicant]
US 8178698B2 · Cannizzo et al. · 2012 [cited by applicant]
US 8299053B2 · Bednarski et al. · 2012 [cited by applicant]
US 8367734B1 · Gao et al. · 2013 [cited by applicant]
US 8471041B2 · Straessler et al. · 2013 [cited by applicant]
US 8664247B2 · Scicinski et al. · 2014 [cited by applicant]
US 8927527B2 · Bednarski et al. · 2015 [cited by applicant]
US 8946167B2 · Hegedus et al. · 2015 [cited by applicant]
US 9139519B2 · Scicinski et al. · 2015 [cited by applicant]
US 9226915B2 · Bednarski et al. · 2016 [cited by applicant]
US 9468625B2 · Scicinski et al. · 2016 [cited by applicant]
US 9498437B2 · Chaudry · 2016 [cited by applicant]
US 9511016B2 · Oronsky et al. · 2016 [cited by applicant]
US 9987270B1 · Oronsky et al. · 2018 [cited by applicant]
US 10149832B2 · Bednarski et al. · 2018 [cited by applicant]
US 10342778B1 · Oronsky et al. · 2019 [cited by applicant]
US 10543208B2 · Oronsky et al. · 2020 [cited by applicant]
US 11008287B2 · Oronsky et al. · 2021 [cited by applicant]
US 11160784B1 · Oronsky et al. · 2021 [cited by applicant]
US 11510901B2 · Oronsky · 2022 [cited by examiner]
US 11576895B2 · Oronsky et al. · 2023 [cited by applicant]
US 11660286B2 · Oronsky et al. · 2023 [cited by applicant]
US 11701351B2 · Oronsky et al. · 2023 [cited by applicant]
US 11744859B2 · Oronsky · 2023 [cited by applicant]
US 11925617B2 · Bednarski et al. · 2024 [cited by applicant]
US 12048793B2 · Oronsky et al. · 2024 [cited by applicant]
US 12109348B2 · Oronsky et al. · 2024 [cited by applicant]
US 20020137770A1 · Nara et al. · 2002 [cited by applicant]
US 20030092684A1 · Fredeking et al. · 2003 [cited by applicant]
US 20040024057A1 · Earl et al. · 2004 [cited by applicant]
US 20040138481A1 · Highsmith et al. · 2004 [cited by applicant]
US 20040167212A1 · Bednarski et al. · 2004 [cited by applicant]
US 20050070872A1 · Sato et al. · 2005 [cited by applicant]
US 20060111272A1 · Roberts et al. · 2006 [cited by applicant]
US 20060211639A1 · Bratzler et al. · 2006 [cited by applicant]
US 20070135384A1 · Bednarski et al. · 2007 [cited by applicant]
US 20080255149A1 · Dobler et al. · 2008 [cited by applicant]
US 20080256149A1 · Bansal et al. · 2008 [cited by applicant]
US 20090093644A1 · Cannizzo et al. · 2009 [cited by applicant]
US 20090163466A1 · Bednarski et al. · 2009 [cited by applicant]
US 20090192085A1 · Robson et al. · 2009 [cited by applicant]
US 20090263483A1 · Desai et al. · 2009 [cited by applicant]
US 20100247682A1 · Gladwin et al. · 2010 [cited by applicant]
US 20100260719A1 · Zeldis · 2010 [cited by applicant]
US 20110130378A1 · Selic · 2011 [cited by applicant]
US 20110130572A1 · Cannizzo et al. · 2011 [cited by applicant]
US 20110195947A1 · Straessler et al. · 2011 [cited by applicant]
US 20120149678A1 · Oronsky et al. · 2012 [cited by applicant]
US 20130053418A1 · Scicinski et al. · 2013 [cited by applicant]
US 20130123216A1 · Bednarski et al. · 2013 [cited by applicant]
US 20130172312A1 · Nosse et al. · 2013 [cited by applicant]
US 20140220163A1 · Babadi et al. · 2014 [cited by applicant]
US 20140308260A1 · Oronsky et al. · 2014 [cited by applicant]
US 20140349988A1 · Scicinski et al. · 2014 [cited by applicant]
US 20150190465A1 · Faivre et al. · 2015 [cited by applicant]
US 20150224104A1 · Gandhi et al. · 2015 [cited by applicant]
US 20150246020A1 · Bednarski et al. · 2015 [cited by applicant]
US 20160081981A1 · Scicinski et al. · 2016 [cited by applicant]
US 20160199346A1 · Bednarski et al. · 2016 [cited by applicant]
US 20180085346A1 · Bednarski et al. · 2018 [cited by applicant]
US 20190125742A1 · Oronsky et al. · 2019 [cited by applicant]
US 20190307723A1 · Oronsky et al. · 2019 [cited by applicant]
US 20200022952A1 · Oronsky et al. · 2020 [cited by applicant]
US 20200046682A1 · Bednarski et al. · 2020 [cited by applicant]
US 20200157047A1 · Oronsky et al. · 2020 [cited by applicant]
US 20200254016A1 · Oronsky · 2020 [cited by applicant]
US 20200345689A1 · Oronsky et al. · 2020 [cited by applicant]
US 20200345690A1 · Oronsky et al. · 2020 [cited by applicant]
US 20200375982A1 · Oronsky et al. · 2020 [cited by applicant]
US 20220016077A1 · Bednarski et al. · 2022 [cited by applicant]
US 20220054480A1 · Oronsky et al. · 2022 [cited by applicant]
US 20230233524A1 · Oronsky et al. · 2023 [cited by applicant]
US 20240122977A1 · Oronsky · 2024 [cited by applicant]
US 20240293360A1 · Reid et al. · 2024 [cited by applicant]
US 20240374562A1 · Oronsky et al. · 2024 [cited by applicant]
US 20240382451A1 · Oronsky et al. · 2024 [cited by applicant]
US 20250049756A1 · Bednarski et al. · 2025 [cited by applicant]
CN 200946766Y · 2007 [cited by applicant]
CN 101370492A · 2009 [cited by applicant]
CN 101708337B · 2011 [cited by applicant]
CN 102458112A · 2012 [cited by applicant]
DE 10111049A1 · 2002 [cited by applicant]
EP 412211A1 · 1991 [cited by applicant]
EP 1336602A1 · 2003 [cited by applicant]
JP S48030376B · 1973 [cited by applicant]
JP S5511509A · 1980 [cited by applicant]
JP H05155847A · 1993 [cited by applicant]
JP 2001507362A · 2001 [cited by applicant]
JP 2001506974A · 2011 [cited by applicant]
JP 2012523414A · 2012 [cited by applicant]
JP 2014530811A · 2014 [cited by applicant]
JP 2017506260A · 2017 [cited by applicant]
RU 2188026C1 · 2002 [cited by applicant]
RU 2265440C2 · 2005 [cited by applicant]
RU 2411953C1 · 2011 [cited by applicant]
WO WO1995032715A1 · 1995 [cited by applicant]
WO WO1996036602A1 · 1996 [cited by applicant]
WO WO1998016485A1 · 1998 [cited by applicant]
WO WO1998016502A1 · 1998 [cited by applicant]
WO WO1999016436A1 · 1999 [cited by applicant]
WO WO1999059575A1 · 1999 [cited by applicant]
WO WO2000006143A1 · 2000 [cited by applicant]
WO WO2001077100A2 · 2001 [cited by applicant]
WO WO2004032864A2 · 2004 [cited by applicant]
WO WO2004098538A2 · 2004 [cited by applicant]
WO WO2004113281A1 · 2004 [cited by applicant]
WO WO2005046661A2 · 2005 [cited by applicant]
WO WO2006102760A1 · 2006 [cited by applicant]
WO WO2007022121A2 · 2007 [cited by applicant]
WO WO2007022225A2 · 2007 [cited by applicant]
WO WO2007042647A1 · 2007 [cited by applicant]
WO WO2012078992A1 · 2012 [cited by applicant]
WO WO2013052164A1 · 2013 [cited by applicant]
WO WO2013052803A2 · 2013 [cited by applicant]
WO WO2015030730A1 · 2015 [cited by applicant]
WO WO2017123593A1 · 2017 [cited by applicant]
WO WO2019164593A2 · 2019 [cited by applicant]
WO WO2019164594A2 · 2019 [cited by applicant]
WO WO2019241276A1 · 2019 [cited by applicant]
WO WO2022068910A1 · 2022 [cited by applicant]
WO WO2022127655A1 · 2022 [cited by applicant]
WO WO2022261284A1 · 2022 [cited by applicant]
Akhavan (2004). “Explosives and Propellants,” Kirk-Othmer Encyclopedia of Chemical Technology, pp. 719-744. [cited by applicant]
Alderman, (1984). “A Review of Cellulose Ethers in Hydrophilic Matrices for Oral Controlled-Release Dosage Forms,” Int. J. Pharm. Tech. & Prod. Mfr., 5(3):1-9. [cited by applicant]
Archibald et al., (1990). “Synthesis and x-ray crystal structure of 1,3,3-trinitroazetidine,” J. Org. Chem., 55:2920-2924. [cited by applicant]
Armstrong et al., (2002). “Role of Glutathione Depletion and Reactive Oxygen Species Generation in Apoptotic Signaling in a Human B Lymphoma Cell Line, Cell Death and Differentiation,” Nature, 9:252-263. [cited by applicant]
Australian Examination Report received for Australian patent application No. 2006279589, dated May 18, 2012, 3 pages. [cited by applicant]
Bamba et al., (1979). “Release Mechanisms in Gelforming Sustained Release Preparations,” Int. J. Pharm., 2:307-315. [cited by applicant]
Berge et al., (1997). “Pharmaceutical Salts,” Journal of Pharmaceutical Sciences, 66(1):1-19. [cited by applicant]
Brown et al., (1998). “Tirapazamine: Laboratory Data Relevant to Clinical Activity,” Anti-Cancer Drug Design, 13:529-539. Abstract Only. [cited by applicant]
Brzezniak et al., (2016). “RRx-001-Induced Tumor Necrosis and Immune Cell Infiltration in an EGFR Mutation-Positive NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors: A Case Report,” Case Rep Oncol., 9:45-50. [cited by applicant]
Cabrales et al., (2016). “A look inside the mechanistic black box: Are red blood cells the critical effectors of RRx-001 cytotoxicity?” Medical Oncology, 33(7):63, 7 Pages. Abstract Only. [cited by applicant]
Carter et al., (2016). “Partial response to carboplatin in an RRx-001 pretreated patient with EGFR-inhibitor-resistance and T790M-negative NSCLC,” Respir. Med. Case Rep., 18:62-65. [cited by applicant]
Chawla et al., (2004). “Challenges in Polymorphism of Pharmaceuticals,” CRIPS, 5(1):12-15. [cited by applicant]
ClinicalTrials.gov, (2015). “NCT02489903: RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (Triple Threat),” Available from the Internet, <ht… [cited by applicant]
ClinicalTrials.gov, (2015). “NCT01359982: Safety and Pharmacokinetic Study of RRx-001 in Cancer Subjects (DINAMIC),” available online at <https://clinicaltrials.gov/ct2/show/NCT02096354?term=RRx-001&draw=1&rank=11>, 7 p… [cited by applicant]
ClinicalTrials.gov, (2016). “NCT02096341: A Phase 1 Pilot Study of the Subcutaneous (s.c.) Route to Facilitate the Administration of RRx-001,” available online at <https://clinicaltrials.gov/ct2/show/NCT02096341?term=RR… [cited by applicant]
ClinicalTrials.gov, (2018). “NCT03515538: Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Oral Cancers (PREVLAR),” retrieved from the interne… [cited by applicant]
ClinicalTrials.gov, (2019). “NCT02489903: RRX-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (Quadruple Threat)”, available online at <https://… [cited by applicant]
Clinicaltrials.gov, (2019). “NCT02452970: RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy (EPIC),” available online at <https://clinicaltrials.gov/ct2/show… [cited by applicant]
ClinicalTrials.gov, (2019). “NCT02518958: A Phase I, Open-Label, Multiple Ascending Dose Study of RRx-001 and Nivolumab (PRIMETIME),” available online at <https://clinicaltrials.gov/ct2/show/NCT02518958?term=RRx-001&dra… [cited by applicant]
ClinicalTrials.gov, (2020). “NCT02871843: Phase 1 Two Part Dose Escalation Trial of RRx-001 + Radiation + Temozolomide and RRx-001 + Temozolomide Post-RT In Newly Diagnosed Glioblastoma and Anaplastic Gliomas (G-FORCE-1… [cited by applicant]
ClinicalTrials.gov, (2021). “NCT02215512: Dose-Escalation Study of RRx-001 in Combination With Whole Brain Radiation in Subjects With Brain Metastases (BRAINSTORM),” available online at <https://clinicaltrials.gov/ct2/s… [cited by applicant]
ClinicalTrials.gov, (2021). “NCT03699956: RRx-001 Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond in Patients With Small Cell Lung Cancer (REPLATINUM),” available online at <https://cl… [cited by applicant]
ClinicalTrials.gov, (2022). “NCT02096354: A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer (ROCKET),” available online at <https://clinicaltrials.gov/ct2/sho… [cited by applicant]
ClinicalTrials.gov, (2022). “NCT02801097: RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer (PAYLOAD) (PAYLOAD),” available online at <https://clinicaltrials.gov/ct2/show/NCT02801097?term=RRx-001&d… [cited by applicant]
ClinicalTrials.gov, (2022). “NCT02871843: RRx-001 + Radiation + Temozolomide In Newly Diagnosed Glioblastoma and Anaplastic Gliomas (G-FORCE-1),” available online at <https://clinicaltrials.gov/ct2/show/NCT02096354?term… [cited by applicant]
ClinicalTrials.gov, (2022). “NCT04525014: RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors (PIRATE),” available online… [cited by applicant]
Coburn et al., (1998). caplus an 1998:567551, RN 179894-08-7, 3 pages. [cited by applicant]
Crowder et al., (1999). “Vibrational analysis of high-energy compounds: 1,3,3-trinitroazetidine and 1-acetyl-3, 3-dinitroazetidine,” Journal of Energetic Materials, 17(1):49-68. [cited by applicant]
Crowder et al., (1999). caplus an 1999:171384, RN 179894-08-7,1 page. [cited by applicant]
Dave et al., (2000). “Convenient Acylative Dealkylation of Tertiary Amines,” Journal of Organic Chemistry, 65:1207-1209. [cited by applicant]
Dave, (1996). “Acylative Dealkylation of N-tert-Butyl-3-substituted Azetidines: Facile Access to [1.1.0] Azabicyclobutane, 3-Hydroxyazetidinium Hydrochloride, and 3-Azetidinones,” J. Org. Chem., 61:5453-5455. [cited by applicant]
Dave, (1997), caplus an 1997:67373, RN 179894-08-7,1 page. [cited by applicant]
Dorman, (2000). “Fulminant babesiosis treated with clindamycin, quinine, and whole-blood exchange transfusion,” Transfusion, 40(3):375-80. [cited by applicant]
Drumond et al., (2013). “Transmissible Venereal Tumor treated with Autohemotherapy,” Acta Scientiae Veterinariae, 41:1107, 4 pages. [cited by applicant]
During et al., (1989). “Controlled Release of Dopamine from a Polymeric Brain Implant: In Vivo Characterization,” Annals of Neurology, 25(4):351-356. Abstract Only. [cited by applicant]
European Supplementary Search Report for European Patent Application No. EP12839088.7, published Apr. 28, 2015, 4 pages. [cited by applicant]
Fareed et al., (2000). “An update on heparins at the beginning of the new millennium,” Semin Thromb Hemost., 26(Suppl 1):5-21, 3 pages. Abstract Only. [cited by applicant]
Feuer et al., (1954). “The Mannich reaction of certain dinitro alcohols with glycine and ethanolamine,” Journal of American Chemical Society, 76:5124-5126. [cited by applicant]
Final Office Action received for U.S. Appl. No. 13/655,618 mailed on Jun. 12, 2014, 6 pages. [cited by applicant]
Final Office Action received for U.S. Appl. No. 13/655,618 mailed on Sep. 11, 2013, 4 pages. [cited by applicant]
Final Office Action received for U.S. Appl. No. 14/965,062 mailed on Feb. 6, 2017, 6 pages. [cited by applicant]
Final Office Action received for U.S. Appl. No. 16/284,035 mailed on May 26, 2022, 28 pages. [cited by applicant]
Final Office Action received for U.S. Appl. No. 16/284,035 mailed on Nov. 15, 2021, 24 pages. [cited by applicant]
Fitch et al., (2013). “Abstract WRM 267: High resolution MS proves that the developmental cancer drug, RRx-001, alkylates the hemoglobin beta chain,” 44th Western Regional Meeting of the American Chemical Society, avail… [cited by applicant]
Garver et al., (1985). “Catalyzed Oxidative Nitration of Nitronate Salts,” J. Org. Chem. 50(10):1699-1702. [cited by applicant]
Gladwin et al., (2005). “The Emerging Biology of the Nitrite Anion,” in Nature Chemistry and Biology, 1:308-31. [cited by applicant]
Goodson, (1984). “Dental Applications,” Chapter 6 of Medical Applications of Controlled Release, 2:115-138. [cited by applicant]
Granelli et al., (2004). “SEL1L and Squamous Cell Carcinoma of the Esophagus,” Clinical Cancer Research, 10:5857-5861. [cited by applicant]
Grisham, (2017). “Pumped Up: Implanted Chemotherapy Device Improves Survival when Colorectal Cancer Spreads to the Liver,” available online at <https://www.mskcc.org/news/pumped-implanted-chemotherapy-device-improves-su… [cited by applicant]
Heller, (2010). “An Electrochemical Engineering Perspective of Nitric Oxide in Tumors: Why the Combination of an Allosteric Effector of Hemoglobin with Dietary Sodium Nitrite Should Be Effective in Treating Vascularized… [cited by applicant]
Hiskey et al., (1993). caplus an 1993:233785, RN 147636-85-9, 1 page. [cited by applicant]
Hiskey et al., (1994). caplus an 1994:700750, RN 158669-97-7, 1 page. [cited by applicant]
Hiskey et al., (1999). “Preparation of 1-Substituted-3,3-Dinitroazetidines,” Journal of Energetic Materials, 17:233-252. [cited by applicant]
Hiskey et al., (1999). caplus an 1999:411860, RN 236102-58-2, 1 page. [cited by applicant]
Hockel et al., (2001). “Tumor Hypoxia: Definitions and Current Clinical, Biologic, and Molecular Aspects,” Journal of the National Cancer Institute, 93(4):266-276. [cited by applicant]
Hong et al., (2008). Combining Targeted Therapies, Targeted Cancer Therapy, p. 362, 2 pAGES. [cited by applicant]
Howard et al., (1989). “Intracerebral Drug Delivery in Rats with Lesion-Induced Memory Deficits,” J. Neurosurg., 71:105-112. [cited by applicant]
Huguenin et al., (2005). “Evaluation of the antitumoral potential of different nitric oxide- donating non-steroidal anti-inflammatory drugs (NO-NSAIDs) on human urological tumor cell lines,” Cancer Letters, 218:163-170. [cited by applicant]
Ignarro, (2000). “Nitric Oxide Biology and Pathology,” Academic Press, pp. 5, 895, and 908. [cited by applicant]
International Preliminary Report on Patentability for PCT/US2019/012696 mailed Jul. 14, 2020, 8 pages. [cited by applicant]
International Preliminary Report on Patentability for PCT/US2019/012701 mailed Jul. 14, 2020, 8 pages. [cited by applicant]
International Search Report and Written Opinion for PCT/US2011/064178 mailed Apr. 17, 2012, 8 pages. [cited by applicant]
International Search Report and Written Opinion for PCT/US2012/038592 mailed Aug. 10, 2012, 11 pages. [cited by applicant]
International Search Report and Written Opinion for PCT/US2012/058964, mailed Apr. 5, 2013, 9 pages. [cited by applicant]
International Search Report and Written Opinion for PCT/US2017/012948 mailed Mar. 28, 2017, 8 pages. [cited by applicant]
International Search Report and Written Opinion for PCT/US2017/056454 mailed Feb. 6, 2018, 12 pages. [cited by applicant]
International Search Report and Written Opinion for PCT/US2018/041138 mailed Oct. 5, 2018, 9 pages. [cited by applicant]
International Search Report and Written Opinion for PCT/US2019/012696 mailed Sep. 6, 2019, 12 pages. [cited by applicant]
International Search Report and Written Opinion for PCT/US2019/012701 mailed Sep. 4, 2019, 12 pages. [cited by applicant]
International Search Report for PCT/US2006/031722 mailed May 29, 2007, 1 page. [cited by applicant]
International Search Report for PCT/US2006/031917 mailed Jul. 20, 2007, 1 page. [cited by applicant]
International Search Report for PCT/US2011/021500 mailed May 3, 2011, 4 pages. [cited by applicant]
Jia et al., (2002). “NO donors with anticancer activity,” Expert Opin. Ther. Pat., 12(6):819-826. [cited by applicant]
Jia, (2008). “A Guide to Pass the National Licensed Pharmacist Examination in Medicinal Chemistry,” pp. 4-11, 9 pages. English abstract. [cited by applicant]
Johnson et al., (2001). “Relationships Between Drug Activity in NCI Preclinical in Vitro and in Vivo Models and Early Clinical Trials,” British J. Cancer, 84(10):1424-1431. [cited by applicant]
Kamran et al., (2016). “Radioprotective Agents: Strategies and Translational Advances,” Medicinal Research Reviews, 36(3):461-493, 33 pages. [cited by applicant]
Kashfi et al., (2002). “Nitric Oxide-Donating Nonsteroidal Anti-Inflammatory Drugs Inhibit the Growth of Various Cultured Human Cancel Cells: Evidence of a Tissue Type-Independent Effect,” J. Pharmacology Experimental T… [cited by applicant]
Katritzky et al., (1994). “Novel Syntheses of 1,3,3-Trinitroazetidine,” J. Heterocyclic Chem., 31:271-275. [cited by applicant]
Kim et al., (2016). “Whole Brain Radiotherapy and RRx-001: Two Partial Responses in Radioresistant Melanoma Brain Metastases from a Phase 1/11 Clinical Trial: A TITE-CRM Phase 1/11 Clinical Trial,” Translational Oncolog… [cited by applicant]
Konovalova et al., (2003). “Nitric oxide donor increases the efficiency of cytostatic therapy and retards the development of drug resistance,” Nitric Oxide, 8(1):59-64. [cited by applicant]
Kornblum et al., (1983). “Oxidative Substitution of Nitroparaffin Salts,” J. Org. Chem., 48:332-337. [cited by applicant]
Langer et al., (1983). “Chemical and Physical Structure of Polymers as Carriers for Controlled Release of Bioactive Agents: A Review,” JMS-Rev. Macromol. Chem. Phys., pp. 61-126. [cited by applicant]
Langer et al., (1984). “Chapter 2: Medical Applications of Controlled Release,” Classes of Systems, pp. 42-67. [cited by applicant]
Langer, (1990). “New Methods of Drug Delivery,” Science, 249(4976):1527-1533. [cited by applicant]
Levy et al., (1985). “Inhibition of Calcification of Bioprosthetic Heart Valves by Local Controlled-Release Diphosphonate,” Science, 228(4696):190-192. [cited by applicant]
Li et al., (2006). caplus an 2006:150006, RN 179894-08-7, 1 page. [cited by applicant]
Li, (2014). “Nursing Comprehensive Skills Training,” China Press of Traditional Chinese Medicine, 3 pages. English abstract. [cited by applicant]
Ling et al., (2005). “Phase I study of CM-Na combined with concurrent radiochemotherapy for advanced esophageal carcinoma,” Chinese Journal of Cancer, 24(5):582-6, 2 pages. Abstract Only. [cited by applicant]
Lopez-Ferrer et al., (2002). “Differences in the O-Glycosylation Patterns Between Lung Squamous Cell Carcinoma and Adenocarcinoma,” Am. J. Clin. Pathol., 118:749-755. [cited by applicant]
Lusk et al., (2004). “Electrochemical Oxidation of Alkylnitro Compounds PP-1345, A SERDP ‘SEED’ Activity,” available online at <https://www.serdp-estcp.org/content/download/6439/85721/file/PP-1345-FR-01.pdf>, 30 pages. [cited by applicant]
Marchand et al., (1994). “Additions of X-Y Across the C(3)-N alpha-Bond in 1-Aza-3-ethylbicyclo[1.1.0]butane, Novel Routes to 3-Substituted Azetidines,” Journal of Organic Chemistry, 59(18):5499-5501. [cited by applicant]
Marchand et al., (1995). “A Novel Approach to the Synthesis of 1,3,3-Trinitroazetidine,” J. Org Chem., 60(15):4943-4946. [cited by applicant]
Maxwell et al., (1997). “Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth,” Proc. Natl. Acad. Sci. USA, 94:8104-8109. [cited by applicant]
McKenney et al., (1998). “Synthesis and thermal properties of 1,3-dinitro-3-(1′,3′-dinitroazetidin-3′-yl) azetidine (TNDAZ) and its admixtures with 1,3,3-trinitroazetidine (TNAZ),” Journal of Energetic Materials, 16:199… [cited by applicant]
Mendenhall et al., (2000). “Radiation Therapy for Squamous Cell Carcinoma of the Tonsillar Region: A Preferred Alternative to Surgery?” J. Clinical Oncology, 18(11):2219-2225. [cited by applicant]
Merck & Co., Inc., (2008). “TEMODAR Prescribing Information,” 17 pages. [cited by applicant]
Miller et al., (2015). “CD47 Receptor Globally Regulates Metabolic Pathways That Control Resistance to Ionizing Radiation,” J. Biol. Chem., 290:24858-24874. [cited by applicant]
Morales-Suarez-Varela et al., (1995). “Impact of Nitrates in Drinking Water on Cancer Mortality in Valencia, Spain,” European Journal of Epidemiology, 11:15-21. [cited by applicant]
Muehlstaedt et al., (1975). caplus an 1976:89768, RN 58373-43-6, 1 page. [cited by applicant]
Nabi et al., (2001). “Primary squamous cell carcinoma of the prostate: a rare clinicopathological entity. Report of 2 cases and review of literature,” Urol. Int., 66(4):216-219. Abstract Only. [cited by applicant]
Naimi et al., (2003). “Synthesis of 3′- and 5′-Nitrooxy Pyrimidine Nucleoside Nitrate Esters: “Nitric Oxide Donor” Agents for Evaluation as Anticancer and Antiviral Agents,” J. Med. Chem., 46:995-1004. [cited by applicant]
Nara et al., (2002). caplus an 2002:169585, RN 402835-09-0, 1 page. [cited by applicant]
Newman et al., (2003). “Solid-state analysis of the active pharmaceutical ingredient in drug products,” Drug Discovery Today, 8(19):898-905. [cited by applicant]
NIH, (2018). “Vascular Tumor,” available online at <https://www.cancer.gov/gublications/dictionaries/cancer-terms/def/vascular-tumor>, 1 page. [cited by applicant]
Ning et al., (2002). “The Antiangiogenic Agents SU5416 and SU6668 Increase the Antitumor Effects of Fractionated Irradiation,” Radiation Research, 157:5-51. [cited by applicant]
Ning et al., (2012). “Dinitroazetidines Are a Novel class of Anticancer Agents and Hypoxia-Activated Radiation Sensitizers Developed from Highly Energetic Materials,” Cancer Res., 72:2600-2608. [cited by applicant]
Ning et al., (2015). “Nrf2 activity as a potential biomarker for the pan-epigenetic anticancer agent, RRx-001,” Oncotarget, 6(25):21547-21556. [cited by applicant]
Nitrates and Nitrites: Answers to Frequently Asked Questions, Ohio Bureau of Environmental Health, Health Assessment Section, Nov. 1, 2006, 2 pages. [cited by applicant]
Oberoi et al, (2013). “Nanocarriers for delivery of platinum anticancer drugs,” Advanced Drug Delivery Reviews, 65(13):1667-1685. [cited by applicant]
Office Action received for U.S. Appl. No. 12/397,651 mailed on Feb. 11, 2011, 10 pages. [cited by applicant]
Office Action received for U.S. Appl. No. 12/397,651 mailed on Feb. 24, 2012, 8 pages. [cited by applicant]
Office Action received for U.S. Appl. No. 13/655,618 mailed on Feb. 25, 2014, 6 pages. [cited by applicant]
Office Action received for U.S. Appl. No. 13/655,618 mailed on May 2, 2013, 9 pages. [cited by applicant]
Office Action received for U.S. Appl. No. 14/849,783 mailed on Jan. 15, 2016, 5 pages. [cited by applicant]
Office Action received for U.S. Appl. No. 14/965,062 mailed on Aug. 11, 2016, 10 pages. [cited by applicant]
Office Action received for U.S. Appl. No. 14/965,062 mailed on Dec. 18, 2017, 8 pages. [cited by applicant]
Office Action received for U.S. Appl. No. 15/298,735 mailed on Aug. 30, 2018, 9 pages. [cited by applicant]
Office Action received for U.S. Appl. No. 15/669,403 mailed on Sep. 14, 2018, 9 pages. [cited by applicant]
Office Action received for U.S. Appl. No. 15/989,862 mailed on Feb. 8, 2019, 6 pages. [cited by applicant]
Office Action received for U.S. Appl. No. 16/284,035 mailed on Apr. 13, 2021, 17 pages. [cited by applicant]
Office Action received for U.S. Appl. No. 16/353,047 mailed on Aug. 31, 2020, 7 pages. [cited by applicant]
Office Action received for U.S. Appl. No. 16/712,148 mailed on Oct. 7, 2020, 7 pages. [cited by applicant]
Office Action received for U.S. Appl. No. 16/960,443 mailed on May 28, 2021, 25 pages. [cited by applicant]
Oronsky et al., (2015). “A Review of Two Promising Radiosensitizers in Brain Metastases: Rrx-001 and 2-Deoxyqlucose,” J. Cancer Sci. Ther., 7(5):137-141. [cited by applicant]
Oronsky et al., (2016). “RRx-001, A novel dinitroazetidine radiosensitizer,” Invest. New Drugs, 34(3):371-377. [cited by applicant]
Oronsky et al., (2017). “RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials”, Expert Opinion on investigational Drugs, 26(1):109-119. [cited by applicant]
Oxley et al., (1997). “Thermal Decomposition Pathways of 1,3,3-Trinitroazetidine (TNAZ), Related 3,3-Dinitroazetidium Salts, and 15N, 13C, and 2H Isotopomers,” Journal of Physical Chemistry A, 101(24):4375-4383. [cited by applicant]
Padwa et al., (1985). “Diastereofacial selectivity in azomethine ylide cycloaddition reactions derived from chiral α-cyanoaminosilanes,” Tetrahedron, 41(17):3529-3535. [cited by applicant]
Peiris et al., (2000). “Structures of dinitroazetidine and three of its carbonyl derivatives,” Journal of Chemical Crvstallographv, 30(10):647-653, 8 pages. [cited by applicant]
Pinkel, (1958). “The use of body surface area as a criterion of drug dosage in cancer chemotherapy,” Cancer Research, 18:853-856. [cited by applicant]
Prezioso et al., (1994). “Genetic Toxicity Evaluation of 1, 3, 3-Trinitroazetidine, vol. IV: Summary Report on the Genotoxicity of TNAZ,” AL/OE-TR-1994-0069 vol. IV of IV, Air Force Materiel Command, Wriqht-Patterson Ai… [cited by applicant]
Rafikova et al., (2004). “Control of Plasma Nitric Oxide Bioactivity by Perfluorocarbons Physiological Mechanisms and Clinical Implications,” Circulation., 110:3573-3580. [cited by applicant]
Raleigh et al., (1999). “P269: Pharmacokinetics of Isotretinoin (ISO) in Rats Following Oral Dosing or Aerosol Inhalation,” British J. Cancer, 80(suppl 2):96. [cited by applicant]
Reid et al., (2014). “Two Case Reports of Resensitization to Previous Chemotherapy with the Novel Hypoxia-Activated Hypomethylating Anticancer Agent RRx-001 in Metastatic Colorectal Cancer Patients,” Case Rep. Oncol., 7… [cited by applicant]
Reid et al., (2015). “Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study,” Lancet Oncol, 16:1133-42, 10 pages. [cited by applicant]
Remington, (1995). “The Science and Practice of Pharmacy,” 19th Edition, vol. II, pp. 1495-1562, 1577-1614, and 1660-1692. [cited by applicant]
Rosenthal, (1999). “A Phase I Single-Dose Trial of Gadolinium Texaphyrin (Gd-Tex), a Tumor Selective Radiation Sensitizer Detectable by Magnetic Resonance Imaging,” Clinical Cancer Research, 5(4):739-745. [cited by applicant]
Rupnow et al., (1998). “p53 Mediates Apoptosis Induced by C-Myc Activation in Hypoxic or Gamma Irradiated Fibroblasts,” Cell Death and Differentiation, 5:141-147. [cited by applicant]
Sandler, (1961). “Clinical evaluation of propatylnitrate in angina pectoris,” British Medical Journal, 2(5269):1741-1744. [cited by applicant]
Sauder, (1989). “A Preliminary Trial of the Programmable Implantable Medication System for Insulin Delivery,” The New England Journal of Medicine, 321(9):574-579. [cited by applicant]
Sausville et al., (2006). “Contributions of Human Tumor Xenografts to Anticancer Development,” Cancer Research, 66(7):3351-3354. [cited by applicant]
Schwartz (2007). “Anemia in patients with cancer: incidence, causes, impact, management, and use of treatment guidelines and protocols,” Am. J. Health-Syst. Pharm., 64(3 Supplement 2):S5-S13. [cited by applicant]
Scicinski et al., (2012). “Preclinical Evaluation of the Metabolism and Disposition of RRx-001, a Novel Investigative Anticancer Agent”, Drug Metabolism and Disposition, 40(9):1810-1816. [cited by applicant]
Scicinski et al., (2014). “Development of methods for the bioanalysis of RRx-001 and metabolites”, Bioanalysis, 6(7):947-956. [cited by applicant]
Scicinski et al., (2015). “NO to cancer: The complex and multifaceted role of nitric oxide and the epigenetic nitric oxide donor, RRx-001,” Redox Biology, 6:1-8. [cited by applicant]
Sefton, (1987). “Implantable Pumps,” CRC Grit. Rev. Biomed. Eng., 14(3):201-237. [cited by applicant]
Shokeir, (2004). “Squamous Cell Carcinoma of the Bladder: pathology, diagnosis and treatment,” BJU International, 93:216-220. [cited by applicant]
Sikder et al., (2004). “1,3,3-Trinitroazetidine (TNAZ), a melt-cast explosive: synthesis, characterization and thermal behavior,” Journal of Hazardous Materials, 113:35-43. [cited by applicant]
Simpson et al., (1994). “Characterization of TNAZ,” UCRL-ID-119672, Lawrence Livermore National Laboratory, 15 pages. [cited by applicant]
Smolen et al., (1984). “Chapter 7: Controlled Drug Bioavailability,” Drug Product Design and Performance, vol. 1, pp. 203-237. [cited by applicant]
Stamler et al., (2002). “Inhaled ethyl nitrite gas for persistent pulmonary hypertension in infants,” The Lancet, 360(9350):2077. [cited by applicant]
Straessler et al., (2012). “Development of a Safe and Efficient Two-Step Synthesis for Preparing 1-Bromoacetyl-3,3-dinitroazetidine, a Novel Clinical Anticancer Candidate,” Organic Process Research & Development, 16:512… [cited by applicant]
Stratford et al., (1998). “Bioreductive drugs into the next millennium,” Anti-Cancer Drug Design, 13:519-528. [cited by applicant]
Thomas, (2016). “Mucositis in Cancer Patients: A Review,” available online at <https://www.uspharmacist.com/article/mucositis-in-cancer-patients-a-review#:˜:text=Mucositis%20is%20a%20common%20complication,the%20gastroin… [cited by applicant]
Treat et al., (1988). “Liposome Encapsulated Doxorubicin: Preliminary Results of Phase I and Phase II Trials,” Liposomes in the Therapy of Infectious Diseases and Cancer, Proceedings of the Ciba-Geigy-Squibb-UCLA Colloq… [cited by applicant]
Verma et al., (2000). “Osmotically Controlled Oral Drug Delivery,” Drug Dev. Ind. Pharm., 26(7):695-708. [cited by applicant]
Watt et al., (1998). “TNAZ Based Melt-Cast Explosives: Technology Review and AMRL Research Directions,” Weapons Systems Division, Aeronautical and Maritime Research Laboratory, Melbourne, Australia. Report DSTO-TR-0702,… [cited by applicant]
Watt et al., (2000). “Evaluation of 1,3,3-Trinitrozaetidine (TNAZ)—A High Performance Melt-Castable Explosive,” Weapons Systems Division, Aeronautical and Maritime Research Laboratory, Melbourne, Australia. Report No. D… [cited by applicant]
West, (1988). “Solid State Chemistry and its Applications,” Wiley, New York, pp. 358 and 365. [cited by applicant]
Weyerbrock et al., (2003). “Selective opening of the blood-brain barrier by a nitric oxide donor and long-term survival in rats with C6 gliomas,” Journal of Neurosurgery, 99(4):728-737. [cited by applicant]
Wilson et al., (1998). “Radiation-activated prodrugs as hypoxia-selective cytotoxins: model studies with nitroarylmethyl quaternary salts,” Anti-Cancer Drug Design, 13:663-685. [cited by applicant]
Wong, (1991). “Chapter 5: Heterobifunctional Cross-Linkers,” Chemistry of Protein Conjugation and Crosslinking, p. 147, 3 pages. [cited by applicant]
Written Opinion of the International Searching Authority for PCT/US2006/031722 mailed May 29, 2007, 3 pages. [cited by applicant]
Written Opinion of the International Searching Authority for PCT/US2006/031917 mailed Jul. 20, 2007, 3 pages. [cited by applicant]
Written Opinion of the International Searching Authority for PCT/US2011/021500 mailed Aug. 9, 2012, 4 pages. [cited by applicant]
Wu et al., (2011). “Reactive impurities in excipients: profiling, identification and mitigation of drug-excipient incompatibility,” in AAPS PharmSciTech., 12(4):1248-1263. [cited by applicant]
Yamaguchi et al., (2001). “Photodynamic Therapy with Motexafin Lutetium (Lu-Tex) Reduces Experimental Graft Coronary Artery Disease,” Transplantation, 71(11):1526-1532. [cited by applicant]
Yarmukhamedov et al., (2005). “One-step synthesis of substituted 3,5-dinitropiperidines and 1,5-dinitro-3,7-diazabicyclo(3.3.1)nonanes from 1,3-dinitropropanes,” Russian Chemical Bulletin, International Edition, 54(2):4… [cited by applicant]
Yen et al., (2004). “18F-FDG Uptake in Squamous Cell Carcinoma of the Cervix is Correlated with Glucose Transporter 1 Expression,” The Journal of Nuclear Medicine, 45(1):22-29. [cited by applicant]
You, (2011). “” Medicinal Chemistry, pp. 585-588, 5 pages. English abstract. [cited by applicant]
Zervoudakis et al., (2017). “Treatment Options in Colorectal Liver Metastases: Hepatic Arterial Infusion,” Visc Med, 33:47-53. [cited by applicant]
Zhang et al., (1998). caplus an 1998:460439, RN 211429-18-4, 1 page. [cited by applicant]
Zhu et al., (2017). “Amino-functionalized nano-vesicles for enhanced anticancer efficacy and reduced myelotoxicity of carboplatin,” Colloids and Surfaces, B, Biointerfaces, 157:56-64. [cited by applicant]
Zuo, (2015). “Chapter 16: Cell Death,” Medical Cell Biology, pp. 230-235, 7 pages. English abstract. [cited by applicant]
Anjaria et al., (2008). “Haemorrhagic shock therapy,” Expert Opinion Pharmacother, 9(6):901-911. Abstract Only. [cited by applicant]
Bailey et al., (2012). “The nitrate-nitrite-nitric oxide pathway: Its role in human exercise physiology,” European Journal Of Sport Science, 12(4):309-320. [cited by applicant]
Bonomi et al., (2023). “PREVLAR: Phase 2a Randomized Trial to Assess the Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Head and Neck Chemoradiotherapy,” Int J Radiat Oncol Bio… [cited by applicant]
Brouse et al., (2015). “Impact of hemoglobin nitrite to nitric oxide reductase on blood transfusion for resuscitation from hemorrhagic shock,” Asian Journal of Transfusion Science, 9(1):55-60. [cited by applicant]
Bueno et al., (2013). “Nitrite Signaling in Pulmonary Hypertension: Mechanisms of Bioactivation, Signaling, and Therapeutics,” Antioxidants & Redox Signaling, 18(14):1797-1809. [cited by applicant]
Cabrales et al., (2017). “The macrophage stimulating anti-cancer agent, RRx-001, protects against ischemia-reperfusion injury,” Expert Review Of Hematology, 10(6):575-582, 19 pages. [cited by applicant]
Cabrales, P., (2019). “RRx-001 Acts as a Dual Small Molecule Checkpoint Inhibitor by Downregulating CD47 on Cancer Cells and SIRP-alpha on Monocytes/Macrophages,” Translational Oncology, 12(4):626-632. [cited by applicant]
Cabrales et al., (2022). “Abstract 10336: Phase 3 Anticancer Agent, RRx-001, Ameliorates Hypoxia-Induced Pulmonary Hypertension,” American Heart Association's 2022 Scientific Sessions And The American Heart Association'… [cited by applicant]
Cabrales et al., (2022). “Abstract 19444: RRx-001, a Hypoxic No. Donor and NLRP3 Inflammasome Inhibitor, in Phase 3 for the Treatment of Cancer, Cardioprotects Following Acute Myocardial Infarction,” Circulation Researc… [cited by applicant]
Cañadas-Lozano et al., (2020). “Blockade of the NLRP3 inflammasome improves metabolic health and lifespan in obese mice,” GeroScience, 42(2):715-725. [cited by applicant]
Caroen et al., (2022). “The NLRP3 inhibitor and Nrf2 Agonist, RRx-001, Ameliorates Non-alcoholic Fatty Liver Disease in Rats,” J. Clin. Lipidol., 16(3):e69, 1 page. Abstract only. [cited by applicant]
Chen et al., (2021). “RRx-001 ameliorates inflammatory diseases by acting as a potent covalent NLRP3 inhibitor,” Cellular & Molecular Immunology, 18:1425-1436. [cited by applicant]
Colclough et al., (2008). “High throughput solubility determination with application to selection of compounds for fragment screening,” Bioorganic & Medicinal Chemistry, 16(13):6611-6616. [cited by applicant]
Cury et al., (2011). “Pain and analgesia: The dual effect of nitric oxide in the nociceptive system,” Nitric Oxide, 25(3):243-254. [cited by applicant]
Deutsches Zentrum für Luft-und Raumfahrt, (2020). “How intense and dangerous is cosmic radiation on the Moon?,” available online at <https://www.dlr.de/content/en/articles/news/2020/03/20200925_how-intense-and-dangerous… [cited by applicant]
Duewell et al., (2010). “NLRP3 inflamasomes are required for atherogenesis and activated by cholesterol crystals that form early in disease,” Nature, 464(7293):1357-1361, 14 pages. [cited by applicant]
Environmental Protection Agency, (2011). “Recommended Use of Body Weight3/4 as the Default Method in Derivation of the Oral Reference Dose,” available online at <https://www.epa.gov/risk/recommended-use-body-weight-34-d… [cited by applicant]
Fang et al., (2022). “RRx-001 Exerts Neuroprotection Against LPS-Induced Microglia Activation and Neuroinflammation Through Disturbing the TLR4 Pathway,” Frontiers in Pharmacology, 13:889383, 20 pages. [cited by applicant]
Fens et al., (2012). “Abstract 3246: Treatment with a Novel Dinitroazetidine, Abdnaz, Improves Nitrite Reductase Activity of Sickle Red Blood Cells,” Blood, American Society Of Hematology, 120(21):3246, 2 pages. [cited by applicant]
Geng et al., (2017). “Prediction of Treatment Response for Combined Chemo- and Radiation Therapy for Non-Small Cell Lung Cancer Patients Using a Bio-Mathematical Model,” Scientific Reports, 7:13542, 12 pages. [cited by applicant]
Ghafouri-Fard et al., (2022). “NLRP3: Role in ischemia/reperfusion injuries,” Front. Immunol., 13:926895, 16 pages. [cited by applicant]
Guo et al., (2013). “Crystal structure and explosive performance of a new CL-20/caprolactam cocrystal,” Journal Of Molecular Structure, 1048:267-273. [cited by applicant]
Harmon et al., (2011). “Radioactive Omission: Where Are the Anti-Radiation Drugs?,” Scientific American, 5 pages. [cited by applicant]
Horn et al., (2022). “Role of Cholesterol-Associated Steatohepatitis in the Development of NASH,” Hepatol. Commun., 6(1):12-35. [cited by applicant]
International Search Report and Written Opinion for PCT/US2011/021500 mailed May 3, 2011, 8 pages. [cited by applicant]
International Search Report and Written Opinion for PCT/US2022/032780 mailed Oct. 12, 2022, 25 pages. [cited by applicant]
International Search Report and Written Opinion for PCT/US2022/033856 mailed Nov. 7, 2022, 17 pages. [cited by applicant]
International Search Report and Written Opinion for PCT/US2023/012834 mailed Jun. 26, 2023, 9 pages. [cited by applicant]
International Search Report and Written Opinion for PCT/US2023/020563 mailed Jul. 25, 2023, 12 pages. [cited by applicant]
International Search Report and Written Opinion for PCT/US2023/020574 mailed Jul. 3, 2023, 12 pages. [cited by applicant]
International Search Report and Written Opinion for PCT/US2023/064591 mailed Jun. 16, 2023, 12 pages. [cited by applicant]
International Search Report and Written Opinion for PCT/US2023/068295 mailed Sep. 26, 2023, 12 pages. [cited by applicant]
International Search Report and Written Opinion for PCT/US2023/078708 mailed Feb. 9, 2024, 13 pages. [cited by applicant]
International Search Report and Written Opinion for PCT/US2023/083149 mailed Mar. 21, 2024, 12 pages. [cited by applicant]
International Search Report and Written Opinion for PCT/US2023/086245 mailed Apr. 22, 2024, 13 pages. [cited by applicant]
Kanter et al., (2022). “Explosive Hazards Identified during the Manufacture and Transportation of 1-Bromoacetyl-3,3-dinitroazetidine (RRx-001),” Organic Process Research & Development, 26(11):3010-3014. [cited by applicant]
Kotani et al., (2009). “A novel oxidized low-density lipoprotein marker, serum amyloid A-LDL, is associated with obesity and the metabolic syndrome,” Atherosclerosis, 204(2):526-531. [cited by applicant]
Landenberger et al., (2012). “Cocrystals of 1,3,5,7-Tetranitro-1,3,5,7-tetrazacyclooctane (HMX),” Crystal Growth & Design, 12(7):3603-3609, 19 pages. [cited by applicant]
Lansley et al., (2011). “Acute Dietary Nitrate Supplementation Improves Cycling Time Trial Performance,” Medicine & Science In Sports & Exercise, 43(6):1125-1131. [cited by applicant]
Lee et al., (2010). “Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease,” Dig. Liver Dis., 42(7):503-508. [cited by applicant]
Li et al., (2022). “Macrophage-associated immune checkpoint CD47 blocking ameliorates endometriosis,” Molecular Human Reproduction, 12 pages. [cited by applicant]
Liu et al., (2020). “TSP1-CD47-SIRPalpha signaling facilitates the development of endometriosis by mediating the survival of ectopic endometrium,” American Journal Of Reproductive Immunology, 83(13236), 11 pages. [cited by applicant]
Ma et al., (2021). “Inhibition of the Inflammasome Activity of NLRP3 Attenuates HDM-Induced Allergic Asthma,” Front. Immunol., 12:718779, 12 pages. [cited by applicant]
Mazzolini et al., (2020). “Significance of Simple Steatosis: An Update on the Clinical and Molecular Evidence,” Cells, 9(11):2458, 19 pages. [cited by applicant]
NASA, (2017). “NASA Protects Its Superheroes From Space Weather,” available online at <https://www.nasa.gov/feature/nasa-protects-its-superheroes-from-space-weather>, 3 pages. [cited by applicant]
National Academies of Sciences, Engineering, and Medicine, (2021). “Consensus Study Report Highlights: Space Radiation and Astronaut Health: Managing and Communicating Cancer Risks,” The National Academies Press, 4 page… [cited by applicant]
NIH, (2022). “Cancer Causes and Prevention” available online at <https://www.cancer.gov/about-cancer/causes-prevention#:%20-:text=Cancer%20prevention%20is%20action%20taken,can%20prevent%20cancer%20from%20developing>, 1 … [cited by applicant]
Office Action received for U.S. Appl. No. 17/223,422 mailed on Sep. 19, 2022, 7 pages. [cited by applicant]
Oral (2021). “Nitric oxide and its role in exercise physiology,” Journal Of Sports Medicine And Physical Fitness, 61(9):1208-1211. Abstract Only. [cited by applicant]
Oronsky et al., (2017). “A brief review of the management of platinum-resistant-platinum-refractory ovarian cancer,” Med. Oncol., 34(6):103, 7 pages. [cited by applicant]
Oronsky et al., (2019). “Cardioprotective Effect of Phase 3 Clinical Anticancer Agent, RRx-001, in Doxorubicin-Induced Acute Cardiotoxicity in Mice,” Molecular Pharmaceutics, 16(7):2929-2934. [cited by applicant]
Oronsky et al., (2020). “Desperate Times, Desperate Measures: The Case for RRx-001 in the Treatment of COVID-19,” Seminars In Oncology, 47(5):305-308. [cited by applicant]
Oronsky et al., (2021). “Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical Development,” Journal of Medicinal Ch… [cited by applicant]
Raghunand et al., (2017). “Magnetic resonance imaging of RRx-001 pharmacodynamics in preclinical tumors,” Oncotarget, 8(60):102511-102520. [cited by applicant]
Raman et al., (2006). “Nonalcoholic fatty liver disease: a clinical approach and review,” Can. J. Gastroenterol., 20(5):345-349. [cited by applicant]
Schindhelm et al., (2007). “Alanine aminotransferase predicts coronary heart disease events: A 10-year follow-up of the Hoorn Study,” Atherosclerosis, 191(2):391-396. [cited by applicant]
Takakura et al., (2006). “Acute onset of ulcerative colitis following an operation for sigmoid colon cancer,” J. Gastroenterol., 41:77-82. Abstract Only. [cited by applicant]
Thorsen et al., (1994). “Administration of drugs by infusion pumps in palliative medicine,” Ann Acad Med Singap, 23(2):209-11. Abstract Only. [cited by applicant]
Urwanisch et al., (2021). “The NLRP3 Inflammasome and Its Role in the Pathogenicity of Leukemia,” Int. J. Mol. Sci., 22(3):1271, 17 pages. [cited by applicant]
Wang et al., (2019). “NLRP3 inhibition improves heart function in GPER knockout mice,” Biochemical And Biophysical Research Communications, 514(3):998-1003, 15 pages. [cited by applicant]
Wang et al., (2022). “Molecular dynamics application of cocrystal energetic materials: A review,” Nanotechnology Reviews, 11(1):2141-2153. [cited by applicant]
Wilke et al., (2017). “Radiation-induced cognitive toxicity: pathophysiology and interventions to reduce toxicity in adults,” Neuro-Oncology, 20(5):597-607. [cited by applicant]
Yonezawa, (2012). “Molecular mechanism underlying delivery of platinum agents to the cancer and kidney,” Drug Delivery System, 27(5):381-388. English abstract. [cited by applicant]
Younossi et al., (2016). “Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes,” Hepatology, 64:73-84. [cited by applicant]
Zhang et al., (2020). “Quantifying methane emissions from the largest oil-producing basin in the United States from space,” Sci. Adv. 6:eaaz5120, 9 pages. [cited by applicant]
Zohari et al., (2020). “Estimation of the Detonation Pressure of Co-crystal Explosives through a Novel, Simple and Reliable Model,” Central European Journal Of Energetic Materials, 17(4):492-505. [cited by applicant]
Achan et al., (2011). “Quinine, an old anti-malarial drug in a modern world: role in the treatment of malaria,” Malar J., 10:144, 12 pages. [cited by applicant]